BMO Capital Markets upgraded shares of Precision BioSciences (NASDAQ:DTIL – Free Report) from a market perform rating to an outperform rating in a report released on Friday, Marketbeat Ratings reports ...

HC Wainwright reiterated their buy rating on shares of Precision BioSciences (NASDAQ:DTIL – Free Report) in a research note issued to investors on Friday,Benzinga reports. HC Wainwright currently has ...

Precision BioSciences gains momentum as iECURE reports positive ECUR-506 data, and analysts forecast significant HBV ...

In a report released today, Jason Zemansky from Bank of America Securities maintained a Hold rating on Arcus Biosciences (RCUS – Research ...

Zimberelimab is under clinical development by Arcus Biosciences and currently in Phase II for Pancreatic Ductal Adenocarcinoma.

Etrumadenant is under clinical development by Arcus Biosciences and currently in Phase II for Metastatic Colorectal Cancer.

Arcus Biosciences, Inc. (NASDAQ:NYSE:RCUS), a biotechnology company focused on developing innovative cancer therapies, has been garnering attention from investors and analysts alike due to its ...

HAYWARD, Calif., December 19, 2024--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and ...

Arcus Biosciences, Inc. (NASDAQ:NYSE:RCUS), a biotechnology company focused on developing innovative cancer therapies, has been garnering attention from investors and analysts alike due to its ...

Long term Arcus Biosciences, Inc. (NYSE:RCUS) shareholders know that all too well, since the share price is down considerably over three years. Unfortunately, they have held through a 65% decline ...

Marcus Freeman has done a tremendous job in Year 3 of his tenure at Notre Dame. The former Ohio State Buckeyes linebacker ...